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I N T R O D U C T I O N
Several novel oral anticoagulant drugs (NOACs) have recently been approved for 
use in patients with non-valvular atrial fibrillation or venous thromboembolic disease.1 
These drugs are either direct thrombin inhibitors (dabigatran) or factor Xa inhibitors 
(rivaroxaban, apixaban, edoxaban) and all have been compared in large randomized 
trials with warfarin. In general, NOACs are considered, at least, non-inferior to warfarin 
in terms of stroke prevention but their risk of bleeding is variable.2 Specific antidotes 
for NOACs are not currently available and concerns about managing bleeding episodes 
have been expressed. The management of a bleeding episode from NOACs has some 
similarities but also differences from the management of bleeding from warfarin.
R I S K  O F  B L E E D I N G  W I T H  N O A C S
All NOACs are associated with lower risk of intracranial or intracerebral bleed-
ing than warfarin. In contrast, the risk of gastrointestinal bleeding with NOACs is not 
lower in comparison with warfarin. More specifically, dabigatran at a dose of 150 mg 
twice daily, rivaroxaban at the usual dose of 20 mg once daily, and edoxaban at the 
high dose of 60 mg daily have higher risk of gastrointestinal bleeding than warfarin. 
Dabigatran at the lower dose of 110 mg twice daily has higher risk only in patients 
above 75 years old. Apixaban, in general, has similar risk of gastrointestinal bleeding 
with warfarin. Bleeding risk from other sites (epistaxis, intraocular, subcutaneous 
hematomas, hematuria) with NOACs is either smaller or equal to the risk of warfarin.2
In order to minimize the risk of bleeding with NOACs some precautions are neces-
sary.3 Renal function should be assessed initially and at least yearly or when a deterio-
ration is suspected. NOACs cannot be used in patients with severe renal dysfunction. 
In moderate renal impairment a smaller dose is recommended. Use of proton pump 
inhibitors (PPI) is recommended in patients at high risk for gastrointestinal bleeding. 
Although drug interactions are fewer with NOACs than with warfarin, it must be 
noted that several concomitant medications may increase the antithrombotic effect of 
dabigatran (verapamil, amiodarone, quinidine), rivaroxaban (HIV protease inhibitors) 
or apixaban (diltiazem). In such cases a dose reduction should be considered. In order 
to reduce bleeding risk, as a general rule, patients with stable coronary artery disease 
who receive NOACs do not need aspirin co-administration.
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AbbreviAtions
aPTT = activated partial thromboplastin 
time
CCU = cardiac care unit
FFP = fresh frozen plasma
HIV = human immunodeficiency virus
ICU = intensive care unit
NOACs = novel oral anticoagulants
PCC = prothrombin complex concentrate
PPI = proton pump inhibitor(s)
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M A N A G E M E N T  O F  B L E E D I N G
The management of a bleeding episode depends on the 
location and the severity. Some forms of bleeding require 
specific intervention. Examples include urgent endoscopy for 
upper gastric blood loss, cauterization for continuing epistaxis 
or surgical evacuation for subdural hematoma. Still, most 
bleeding episodes will eventually stop spontaneously. There-
fore, just discontinuation of the drug, while taking general 
supportive measures, is sufficient. Ensuring adequate urine 
output, administration of fluid or colloids, blood transfusion or 
administration of fresh frozen plasma (as volume expander and 
not as a reversal agent) are usual and important non-specific 
measures. Drug elimination depends on renal function. The 
longest drug effect is expected in patients treated with dabi-
gatran who have a reduced creatinine clearance. In patients 
with good renal function coagulation is back to normal within 
12-24 hours for all NOACs (Table 1).
There are no specific antidotes for NOACs (at least clini-
cally available currently) and the administration of vitamin 
K, protamine or fresh frozen plasma (FFP) are ineffective.4 
Prothrombin complex concentrate (PCC), which is particularly 
effective in reversing quickly coagulopathy from vitamin-K 
antagonists, may be tried at a dose of 25 u/kg once or twice with 
NOACs but there is no clinical evidence of benefit. In healthy 
volunteers who were treated with dabigatran, PCC had no ef-
fect on aPTT. In contrast, in healthy volunteers treated with 
rivaroxaban, PCC corrected the prolonged PT value within 
15 min.5 Similar lack of evidence for any benefit applies for 
activated factor VII which may be given as an off-label option. 
High dose of recombinant factor VII (rFVII) (7.2 mg) reduces 
dabigatran-associated bleeding.6
Dabigatran can be removed from the circulation by dialysis. 
In a small open study, 6 patients with end stage renal disease 
were given a 50 mg dose of dabigatran. At 4 hours, 68% of 
the drug was removed by dialysis.7 The anti-Xa agents due to 
high plasma binding are not expected to significantly reduce 
their plasma level with dialysis.
The use of activated charcoal may inhibit further absorp-
tion of any NOAC, provided it is given within the first few 
hours from the last dose.
Specific antidotes are being developed and tested. For 
dabigatan the reversal agent is an antibody fragment that 
does not induce hypercoagulability. For the anti- Xa agents 
a recombinant protein is being developed. It acts as a decoy 
that binds the anti- Xa drug in the blood. Both antidotes are 
currently being tested in phase II studies.
In clinical practice, what is reassuring is that the outcome 
of a patient who bled with a NOAC is no worse than that of 
a patient who bled with warfarin. In the RE-LY trial patients 
who had intracranial bleeding on dabigatran or warfarin had 
similar mortality.8 A recent analysis of 5 randomized trials 
comparing dabigatran with warfarin reported the 30 day out-
TABLE 1. Time to normalization of coagulation and therapeutic options in case of bleeding with novel anticoagulant drugs.
NOAC Time to normalization of hemostasis Options
Dabigatran 12-24 h (CrCl >80 ml/min)
24-36 h (CrCl 50-80 ml/min)
36-48 h (CrCl 30-50 ml/min)
>48 h (CrCl <30 ml/min)
Maintain adequate diuresis, fluid replacement, supportive measures
Dialysis (4 h at 200 ml/min)
PCC 25 u/kg
rVII (off-label)
FFP only as volume expander
Antidote: monoclonal Ab (phase II)
Rivaroxaban 12-24 h Fluid replacement, supportive measures
PCC 25 u/kg
rVII (off-label)
FFP only as volume expander
Antidote: PRTT4445 r-protein Xa (phase II)
Apixaban 12-24 h Fluid replacement, supportive measures
PCC 25 u/kg
rVII (off-label)
FFP only as volume expander
Antidote: PRTT4445 r-protein Xa (phase II)
Ab = antibody; CrCl = creatinine clearance; h = hour(s); NOAC=novel oral anticoagulant drug; PCC=prothrombin complex concentrate; 
FFP=fresh frozen plasma; rVII=recombinant factor VII.
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comes of 1034 patients who suffered a major bleed. Mortal-
ity was non-significantly lower for dabigatran in comparison 
with warfarin.9 This result confirms the notion that the lack 
of a specific antidote is not as important as one might think. 
Moreover, in this report the length of stay in ICU/CCU was 
shorter with dabigatran.
A F T E R  T H E  B L E E D I N G  E P I S O D E
The need to continue with anticoagulation must be reas-
sessed after the bleeding episode. If the risk of recurrent 
hemorrhage is considered smaller than the thrombotic risk of 
atrial fibrillation, anticoagulation should be resumed. Avoid-
ing concomitant drugs, especially aspirin and non-steroidal 
anti-inflammatory drugs is important. Use of PPI in case of 
upper gastrointestinal bleeding is recommended. Renal func-
tion must be checked and a smaller dose of NOAC might be 
considered. If dabigatran was given at the high dose of 150 
mg twice daily then switching to 110 mg twice daily is reason-
able. This dose has been tested and found non-inferior to 
warfarin. Rivaroxaban has been given at a dose 15 mg daily 
and apixaban at a dose 2.5 mg twice daily in patients with 
renal dysfunction, but it is unclear whether these smaller 
doses are effective in stroke prevention when administered 
to patients with normal renal function who have bled with 
the standard dose.
Switching to a different agent is an option but it should 
be mentioned that there are no direct comparisons between 
different NOACs. In the case of gastrointestinal bleeding, 
apixaban is probably safer.
Switching to vitamin-K antagonist is also a fair option, since 
anticoagulation intensity can be monitored. In this case we 
may accept a small increase in intracerebral hemorrhage risk.
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